In the present work, we obtained polymeric diacetylene liposomes that can associate N-Acetyl-l-Cysteine (NAC), a broad spectrum mucolytic. The reason for studying these formulations is that they could be applied in the future as NAC delivery systems, with a possible dose reduction but maintaining its effect.

Liposomes used herein are obtained by a photopolymerization reaction, thus gaining stability and rigidity. Lipids belonging to lung surfactant were added in different ratios to the formulations in order to maximize its possible interaction with the lung tissue. Because of lipopolymer stability, the oral or nasal route could be appropriated. This formulation could efficiently transport NAC to exert its mucolytic activity and help in diseases such as cystic fibrosis, which has abnormal mucus production. Also, this type of treatment could be useful in other types of diseases, interacting with the mucus layer and making the lung tissue more permeable to other therapies.

Formulations so obtained presented high levels of polymerization. Also, they present small hollow fibers structures with a high number of polymeric units. These types of arrangements could present advantages in the field of drug delivery, giving the possibility of a controlled release. Lipopolymers with lipids from lung surfactant associated with NAC are promising complexes in order to treat not only respiratory illnesses. The stability of the formulation would allow its inoculation through other routes such as the oral one, helping the reposition of NAC as an antioxidant drug. Finally, these formulations are non-toxic and easy to produce.

在本工作中，我们获得了可以与N-乙酰基-1-半胱氨酸（NAC）缔合的聚合物二乙炔脂质体，NAC是一种广谱的黏液溶解剂。研究这些制剂的原因是，它们将来可以作为NAC输送系统应用，可能会减少剂量，但保持其效果。

本文中使用的脂质体通过光聚合反应获得，从而获得稳定性和刚性。将属于肺表面活性剂的脂质以不同比例添加到制剂中，以使其与肺组织的可能相互作用最大化。由于脂聚合物的稳定性，可以采用口服或经鼻途径。该制剂可有效转运NAC以发挥其粘液溶解活性，并有助于解决诸如粘液产生异常的囊性纤维化之类的疾病。同样，这种类型的治疗可用于其他类型的疾病，与粘液层相互作用并使肺组织对其他疗法更具渗透性。

如此获得的制剂表现出高聚合水平。而且，它们呈现出具有大量聚合物单元的小的中空纤维结构。这些类型的布置可以在药物输送领域呈现优势，从而提供了受控释放的可能性。具有与NAC相关的肺表面活性剂脂质的脂聚合物是有前途的复合物，不仅可以治疗呼吸系统疾病。制剂的稳定性将使其可通过其他途径（如口服途径）进行接种，从而有助于将NAC定位为抗氧化剂。最后，这些制剂无毒且易于生产。